What we are studying
The purpose of this research study is to see if the investigational drug, LY3314814 can slow the progression of Alzheimer’s disease. LY3314814 is an investigational drug. This means it has not been approved by the U.S. Food and Drug Administration (FDA). Drugs that do not have approval by the FDA cannot be sold or prescribed by your physician. In this study LY3314814 will be compared to a placebo. A placebo is a substance, like a sugar pill, that is not thought to have any effect on your disease or condition. In this study you will either receive the active study medication, LY3314814 or a placebo which is not active. Placebos are used in research studies to see if the drug being studied really does have an effect.
Screening 1, 8, 12, 16, 21, 25, 29, 30 & follow-up: $50 each. Screening 2: $25. Screening 3: $75. Visit 3, 4, 5, 10, 14, 15, 17, 18, 23, 27, & 28: $20 each. Visit 6, 7, 11, 19, 20, & 24: $30 each. PET scan OR lumbar puncture on visit 15, 29, or 30: $75.